tiprankstipranks
LungLife AI’s LungLB Test Gains Prestigious Recognition
Company Announcements

LungLife AI’s LungLB Test Gains Prestigious Recognition

LungLife AI, Inc. (GB:LLAI) has released an update.

Don't Miss Our Christmas Offers:

LungLife AI, Inc. has announced the acceptance of two abstracts related to its LungLB test by the Association for Molecular Pathology for presentation and publication. These abstracts, which confirm the test’s analytic and clinical validity, will be featured at the AMP’s Annual Meeting & Expo and in The Journal of Molecular Diagnostics. The company views this as a crucial step towards the commercialization of LungLB, a blood-based diagnostic test aimed at early detection of lung cancer.

For further insights into GB:LLAI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskLungLife AI Advances Toward LungLB® Commercialization
TipRanks UK Auto-Generated NewsdeskLungLife AI Confident Amid Board Change
TipRanks UK Auto-Generated NewsdeskLungLife AI Revamps Stock Options Amid Cancer Test Advances
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App